多指标免疫检测区分儿童细菌与病毒感染验证
在儿科医院按CLSI指南验证MeMed-BV免疫检测的分析性能,并用60例急诊发热患儿血浆样本回顾性评估临床性能。结果显示敏感性94%、特异性88%,与厂商数据一致性R=0.998,分类细菌感染优于白细胞计数、降钙素原和C反应蛋白。
要点
- MeMed-BV区分儿童细菌与病毒感染敏感性94%、特异性88%。
- 该检测分类细菌感染优于白细胞计数、降钙素原和C反应蛋白。
- 严重脂血对中等病毒可能性样本可致明显偏倚,溶血和黄疸无影响。
核心结论
- MeMed-BV免疫检测分析性能可接受,能可靠区分儿童病毒与细菌感染或共感染。
研究设计与样本
- 按临床和实验室标准协会(CLSI)指南在儿科医院验证MeMed-BV在MeMed Key分析仪上的分析性能。
- 分析性能评估包括精密度(批内和批间)、方法比较和干扰研究。
- 临床性能通过回顾性队列研究评估,样本为60例因急性发热就诊于急诊的儿科患者血浆。
主要发现
- 批内和批间精密度在高分值细菌对照和低分值病毒对照中均小于3个评分单位。
- 识别细菌感染或共感染的敏感性为94%,特异性为88%。
- 本检测结果与厂商实验室数据一致性极好(R=0.998),与ELISA研究可比。
- 严重溶血和黄疸不影响检测,但严重脂血在中等病毒可能性样本中显示明显偏倚。
- MeMed-BV分类细菌感染优于常规测量的感染相关生物标志物如白细胞计数、降钙素原和C反应蛋白。
关键数值与推荐
- 敏感性94%、特异性88%用于识别细菌感染或共感染。
- 与厂商实验室数据一致性R=0.998。
- 精密度在高分值细菌和低分值病毒对照中均小于3个评分单位。
临床怎么用
- 可用于儿科急性发热患儿区分病毒与细菌感染或共感染。
- 严重脂血样本可能影响结果判读,需注意样本质量。
局限性
- 回顾性队列样本量60例,需未来研究评估临床效用,尤其减少血培养需求和缩短治疗时间方面。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical presentation of viral and bacterial infections or co-infections overlaps significantly. Pathogen identification is the gold standard for appropriate treatment. Recently, FDA cleared a multivariate index test called MeMed-BV that distinguishes viral and bacterial infections based on the differential expression of 3 host proteins. Here, we sought to validate MeMed-BV immunoassay on MeMed Key analyzer in our pediatric hospital following guidelines from the Clinical and Laboratory Standards Institute. METHODS: The analytical performance of the MeMed-BV test was evaluated with precision (intra- and inter-assay), method comparison and interference studies. The clinical performance (diagnostic sensitivity and specificity) of the MeMed-BV test was assessed by conducting a retrospective cohort study (n = 60) using plasma samples from pediatric patients with acute febrile illness who visited the emergency department of our hospital. RESULTS: MeMed-BV showed acceptable intra- and inter-assay precision with a range of < 3 score units in both the high-score bacterial as well as the low-score viral controls. Diagnostic accuracy studies revealed a sensitivity of 94% and specificity of 88% for identifying bacterial infections or co-infections. Our MeMed-BV results showed an excellent agreement (R = 0.998) with manufacturer's laboratory data and compared well with ELISA studies. Gross hemolysis and icterus did not affect the assay, but gross lipemia showed a considerable bias in samples with moderate likelihood of viral infection. Importantly, the MeMed-BV test performed better than routinely measured infection-related biomarkers like white blood cell counts, procalcitonin and C-reactive protein in classifying bacterial infections. CONCLUSION: MeMed-BV immunoassay demonstrated acceptable analytical performance and is reliable for distinguishing viral and bacterial infections or co-infections in pediatric patients. Future studies are warranted to examine the clinical utility, especially with respect to reducing the need for blood cultures and time to treatment for the patient.
引用
- Chokkalla AK, Tam E, Liang R, et al. Validation of a multi-analyte immunoassay for distinguishing bacterial vs. viral infections in a pediatric cohort. Clin Chim Acta. 2023. PMID: 37201742. doi:10.1016/j.cca.2023.117387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。